Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs
Clene (NASDAQ: CLNN) releases Q2 2024 financial results and provides updates on CNM-Au8(R) programs for treating ALS and Rett Syndrome. The company's potential new drug application offers hope to patients with critical time needs.
This news matters because Clene's potential new drug application could offer hope to patients with ALS and Rett Syndrome, addressing critical time needs for treatment.